Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News Feature
  • Published:

Biotechnology: Crossing the barrier

Researchers have rallied round a promising molecule for rescuing dying nerves. But getting it into the brain remains a daunting challenge, finds Brian Vastag.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Airaksinen, M. S. & Saarma, M. Nature Rev. Neurosci. 3, 383-394 (2002).

    Article  CAS  Google Scholar 

  2. Gill, S. S. et al. Nature Med. 9, 589-595 (2003).

    Article  CAS  Google Scholar 

  3. Love, S. et al. Nature Med. 11, 703-704 (2005).

    Article  CAS  Google Scholar 

  4. Pardridge, W. M., Kang, Y. S., Buciak, J. L. & Yang, J. Pharm. Res. 12, 807-816 (1995).

    Article  CAS  Google Scholar 

  5. Pardridge, W. M. & Boado, R. J. Pharm. Res. 26, 2227-2236 (2009).

    Article  CAS  Google Scholar 

Download references

Authors

Additional information

Brian Vastag is a freelance reporter in Washington DC.

Related links

Related links

Related links in Nature Research

Biotechnology@nature.com

Related external links

ArmaGen Technologies

Ceregene

MedGenesis Therapeutix

Amgen announces end of GDNF testing

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vastag, B. Biotechnology: Crossing the barrier. Nature 466, 916–918 (2010). https://doi.org/10.1038/466916a

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/466916a

This article is cited by

Search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research